Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
15.6
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025 to 31 March 2026ConsolidatedJapanese GAAPNet Sales29,672¥ millionYear on year +4.6%Progress 88.8%
Operating profit12,156¥ millionYear on year +15.6%Progress 98.8%
Ordinary income12,447¥ millionYear on year +14.0%Progress 99.6%
Net income attributable to owners of the parent9,074¥ millionYear on year +21.0%Progress 103.1%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥365.74
Operating Margin41.0%
Financial position at period-end
Total assets62,679¥ million
of which net assets 54,567 ¥ millionEquity ratio 87.1%vs. prior year-end -0.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+9,038
Investment-8,350
Financials-3,596
Net change-2,908
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥22,009 million
Segment revenuePharmaceuticals business ¥26,926 million (YoY +11.5%), Equipment business ¥2,746 million (YoY -34.7%)
Segment profitPharmaceuticals business ¥12,716 million (YoY +19.1%), Equipment business ¥413 million (YoY -44.2%)
Regional sales¥6,464 million, ¥11,913 million, ¥4,679 million, ¥2,382 million, ¥2,967 million, ¥1,264 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥33,400 million (YoY +12.6%)
Operating profit¥12,300 million (YoY +1.2%)
Ordinary income¥12,500 million (YoY +0.4%)
Net income¥8,800 million (YoY -3.0%)
Annual Dividend Forecast¥95 → ¥180
Payout ratio26.0% (actual for the fiscal year ended March 2026), 50.4% (forecast for the fiscal year ending March 2027)
Factors Behind Changes in Business Performance
Chemical sales for the electronics sector increased as demand for high-performance electronic devices and semiconductor package substrates remained strong. Demand for chemicals used in the decorative sector also increased as automobile production rose in China. The equipment business recorded lower revenue and profit as revenue and order backlog declined significantly.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsNo applicable matters.
Impairment loss¥8 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥20 million, Reversal of asset retirement obligations ¥151 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Loss on Disposal of Fixed Assets ¥13 million, Impairment Losses ¥8 million, Loss on liquidation of subsidiaries ¥27 million
Depreciation and amortization¥1,012 million
Orders received and order backlogOrders received ¥1,794 million / Order backlog ¥397 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End26,219,049 shares
Treasury Shares at Period-End1,599,326 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025 to 31 March 2026 |
| Net Sales | ¥29,672 million (YoY +4.6%) |
| Operating profit | ¥12,156 million (YoY +15.6%) |
| Ordinary income | ¥12,447 million (YoY +14.0%) |
| Profit attributable to owners of the parent | ¥9,074 million (YoY +21.0%) |
| Net income per share | ¥365.74 |
| Operating Margin | 41.0% |
| Equity ratio | End of the current fiscal period 87.1% / End of previous period 87.2% |
| Total assets | ¥62,679 million |
| Net assets | ¥54,567 million |
| Cash flows from operating activities | ¥9,038 million |
| Cash flows from investing activities | ¥-8,350 million |
| Cash flows from financing activities | ¥-3,596 million |
| Cash and cash equivalents at end of period | ¥22,009 million |
| Full-year earnings forecast | Net Sales ¥33,400 million (YoY +12.6%) / Operating profit ¥12,300 million (YoY +1.2%) / Ordinary income ¥12,500 million (YoY +0.4%) / Net income ¥8,800 million (YoY -3.0%) |
| Annual Dividend Forecast | ¥95 → ¥180 |
| Payout ratio | 26.0% (actual for the fiscal year ended March 2026), 50.4% (forecast for the fiscal year ending March 2027) |
| Segment revenue | Pharmaceuticals business ¥26,926 million (YoY +11.5%), Equipment business ¥2,746 million (YoY -34.7%) |
| Segment profit | Pharmaceuticals business ¥12,716 million (YoY +19.1%), Equipment business ¥413 million (YoY -44.2%) |
| Regional sales | ¥6,464 million, ¥11,913 million, ¥4,679 million, ¥2,382 million, ¥2,967 million, ¥1,264 million |
| Orders received and order backlog | Orders received ¥1,794 million / Order backlog ¥397 million |
| Depreciation and amortization | ¥1,012 million |
| Impairment loss | ¥8 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥20 million, Reversal of asset retirement obligations ¥151 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Loss on Disposal of Fixed Assets ¥13 million, Impairment Losses ¥8 million, Loss on liquidation of subsidiaries ¥27 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 26,219,049 shares |
| Treasury Shares at Period-End | 1,599,326 shares |
| Factors Behind Changes in Business Performance | Chemical sales for the electronics sector increased as demand for high-performance electronic devices and semiconductor package substrates remained strong. Demand for chemicals used in the decorative sector also increased as automobile production rose in China. The equipment business recorded lower revenue and profit as revenue and order backlog declined significantly. |
Items this document does not state (2)
Revision to Earnings ForecastShareholder Return Policy
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the electronics sector, demand for high-performance electronic devices such as smartphones, personal computers and servers remained strong, resulting in higher chemical sales. In China, demand for automotive parts increased as automobile production rose. Meanwhile, revenue and order backlog in the equipment business declined significantly.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.